3810-11-5

Basic information

• Product Name: (3-AMINO-4-PYRIDINYL)PHENYLMETHANONE
• Synonyms: (3-AMINO-4-PYRIDINYL)PHENYLMETHANONE;3-AMINO-4-BENZOYLPYRIDINE;(3-AMinopyridin-4-yl)(phenyl)Methanone
• CAS NO: 3810-11-5
• Molecular Formula: C₁₂H₁₀N₂O
• Molecular Weight: 198.22
• Mol File: 3810-11-5.mol
• Article Data: 13

Chemical Properties

• Melting Point: 126-128 °C
• Boiling Point: 423.7 °C at 760 mmHg
• Flash Point: 210.1 °C
• Appearance: /
• Density: 1.215 g/cm³
• Storage Temp.: 2-8°C
• PKA: 4.03±0.18(Predicted)
• CAS DataBase Reference: (3-AMINO-4-PYRIDINYL)PHENYLMETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (3-AMINO-4-PYRIDINYL)PHENYLMETHANONE(3810-11-5)
• EPA Substance Registry System: (3-AMINO-4-PYRIDINYL)PHENYLMETHANONE(3810-11-5)

Safety Data

• Hazardous Substances Data: 3810-11-5(Hazardous Substances Data)

Usage

General Description

(3-Amino-4-pyridinyl)phenylmethanone is a chemical compound with the molecular formula C12H10N2O. It consists of a pyridine ring attached to a phenylmethanone group through an amino group. (3-AMINO-4-PYRIDINYL)PHENYLMETHANONE is used in the synthesis of various pharmaceuticals and organic compounds. It may also have potential applications in the fields of medicine and material science due to its unique structure and properties. Additionally, it is important to handle this compound with care and follow proper safety precautions when working with it in a laboratory setting.

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 100-52-7 benzaldehyde 
• 112175-41-4 tert-butyl (4-(hydroxy(phenyl)methyl)pyridin-3-yl)carbamate 
• 82791-70-6 2,2-Dimethyl-N-<4-(hydroxyphenylmethyl)-3-pyridinyl>propanamide 
• 56700-70-0 3-(tert-butoxycarbonylamino)pyridine 
• 1696-17-9 N,N-diethylbenzamide 
• 14548-46-0 4-Benzoylpyridine 
• 100-47-0 benzonitrile 
• 70298-88-3 N-(pyridin-3-yl)pivalamide 
• 164219-72-1 4-benzoyl-3-nitropyridine 
• 112175-40-3 3-tert-butoxycarbonylamino-4-benzoylpyridine 
• 112175-38-9 N-(4-benzoylpyridin-3-yl)-2,2-dimethylpropionamide 

Downstream Products

• 1373775-06-4 4-phenyl-1,7-naphthyridine-2(1H)-thione 
• 1373774-98-1 3-isocyano-4-(1-phenylethenyl)pyridine 
• 1373774-90-3 N-[4-(1-phenylethenyl)pyridin-3-yl]formamide 
• 1373774-82-3 4-(1-phenylethenyl)pyridin-3-amine 
• 1373774-74-3 1-(3-aminopyridin-4-yl)-1-phenylethanole 
• 1258538-84-9 N-(4-benzoylpyridin-3-yl)formamide 
• 947410-35-7 (3-amino-1-oxidopyridin-4-yl)(phenyl)methanone 
• 289686-53-9 N-(4-benzoyl-pyridin-3-yl)-2-(3,5-bis-trifluoromethyl-phenyl)-isobutyramide 
• 3810-18-2 1,3-dihydro-5-phenyl-2H-pyrido<3,4-e>-1,4-diazepin-2-one 
• 112175-39-0 1,3-dihydro-1-methyl-5-phenyl-2H-pyrido<3,4-e>-1,4-diazepin-2-one 
• 1061210-97-6 (1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-pyrido[3,4-e][1,4]diazepin-3-yl)-carbamic acid benzyl ester 
• 1056885-00-7 (2-Oxo-5-phenyl-2,3-dihydro-1H-pyrido[3,4-e][1,4]diazepin-3-yl)-carbamic acid benzyl ester 
• 170228-93-0 3-amino-2,3-dihydro-1-methyl-5-phenyl-1H-pyrido[3,4-e]-1,4-diazepine-2-one 
• 872890-46-5 N-(4-benzoylpyridin-3-yl)-2,2,2-trichloroacetamide 

Relevant articles and documents

Quinolinones as Inhibitors of Translation Initiation Complex

Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.

COMPOUNDS

The present invention provides a compound incorporating a group of formula (I) wherein: 1 of X, Y and Z is nitrogen and the other 2 are carbon; R" is hydrogen, methyl, ethyl or propyl; and W represents hydrogen, carbon, nitrogen, oxygen or sulphur; or incorporating a salt, hydrate or solvate of a group of formula (I); as well as therapeutic uses of these compounds, in particular as inhibitors of protein kinase activity and in the treatment of inflammation, inflammatory conditions and cancer.

Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase

A novel series of aminopyridine N-oxides were designed, synthesized, and tested for their ability to inhibit p38α MAP kinase. Some of these compounds showed a significant reduction in the LPS-induced TNFR production in human whole blood. Structure-activit